CRL Intrinsic Stock Value – Charles River Laboratories International Acquires 80% Ownership Stake in SAMDI Tech for $50M Cash.
January 31, 2023
Trending News 🌥️
CRL Intrinsic Stock Value – Charles River Laboratories ($NYSE:CRL) International, Inc. (NYSE: CRL) is a global provider of services and products to the life sciences industry. The company offers preclinical and clinical drug development services, as well as a variety of early-stage discovery and development services to biopharmaceutical companies, government agencies, and academic institutions. Charles River recently announced the acquisition of an 80% ownership stake in SAMDI Tech, a Chicago, Illinois-based high-throughput screening solutions provider. According to Charles River, the transaction is not expected to have a material impact on their financial results in 2023. Charles River chief executive officer James Foster said, “We are pleased to announce the acquisition of SAMDI Tech, which provides us with a new technology platform that can be used across our entire preclinical portfolio”.
He went on to say that the acquisition will enable the company to offer more comprehensive drug discovery services to its clients. The purchase of SAMDI Tech is consistent with Charles River’s strategy of investing in and developing technologies that will help them provide better, faster and more cost-effective services to their customers. By adding SAMDI Tech to their existing offerings, Charles River will be able to offer further value to its customers by offering the latest technologies for drug discovery and development. The acquisition of SAMDI Tech will also enable Charles River to expand its presence in the life sciences industry, as well as strengthen its ability to deliver high-quality services and products. With this acquisition, Charles River is aiming to become a leading provider of life sciences services and products.
Share Price
The stock opened at $242.4 and closed at $239.8, down 2.2% from last closing price of $245.1. The acquisition of SAMDI Tech comes as part of CRL’s strategic growth initiatives to expand in the life science sector. SAMDI Tech is a privately owned company that specializes in the development of high-throughput screening (HTS) systems for drug discovery and development. The company also provides a range of services such as custom design and engineering, prototype development, and laboratory testing. The acquisition is expected to enhance CRL’s portfolio of drug discovery and development services, and will provide customers with access to highly advanced technology and services that can help to speed up the drug development process.
CRL believes the acquisition will bring significant value to its operations by enabling it to reduce costs and improve efficiency. CRL believes the acquisition is a strategic move that will strengthen its core competencies and create long-term value for its shareholders. Overall, the acquisition of SAMDI Tech is a positive step forward for CRL as it seeks to expand its life science operations. The company is confident that the acquisition will provide customers with enhanced services and capabilities that will lead to improved outcomes in drug development. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for CRL. More…
| Total Revenues | Net Income | Net Margin |
| 3.78k | 436.39 | 11.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for CRL. More…
| Operations | Investing | Financing |
| 614.14 | -643 | -12.41 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for CRL. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 7.38k | 4.71k | 51.63 |
Key Ratios Snapshot
Some of the financial key ratios for CRL are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 14.3% | 24.2% | 15.3% |
| FCF Margin | ROE | ROA |
| 7.4% | 13.7% | 4.9% |
VI Analysis – CRL Intrinsic Stock Value
CHARLES RIVER LABORATORIES INTERNATIONAL is a company that has long-term potential, and its fundamentals can be easily analyzed with the help of VI app. Our proprietary VI Line has calculated the fair value of CHARLES RIVER LABORATORIES INTERNATIONAL share to be around $299.4. However, the current stock price of CHARLES RIVER LABORATORIES INTERNATIONAL is $239.8, representing an undervalued price of 19.9%. This presents an opportunity to buy the stock at a lower price than what it is really worth. Investors should look into CHARLES RIVER LABORATORIES INTERNATIONAL and its fundamentals to determine whether or not it is a good investment. The company has a history of success and its fundamentals can be easily analyzed with the help of VI app. Furthermore, the current stock price is undervalued by 19.9%, presenting an opportunity to buy the stock at a discounted rate. Investing in CHARLES RIVER LABORATORIES INTERNATIONAL could prove to be a profitable decision for investors who are looking for long-term potential. More…
VI Peers
The global market for contract research services is growing rapidly as more and more companies are outsourcing their research and development needs. This growth is being driven by the increasing costs of R&D, the need for faster timelines, and the desire to tap into the expertise of experienced professionals. As the market expands, so does the competition, and Charles River Laboratories International Inc is up against some stiff competition from the likes of Microba Life Sciences Ltd, IDenta Corp, and Eurofins Scientific SE.
– Microba Life Sciences Ltd ($ASX:MAP)
Denta Corp is a publicly traded company that provides dental products and services. The company has a market capitalization of 1.5 million as of 2022 and a return on equity of -10.42%. The company’s products and services include dental implants, dentures, and other dental prosthetics. Denta Corp also provides dental education and training services. The company was founded in 2006 and is headquartered in New York, New York.
– IDenta Corp ($OTCPK:IDTA)
Eurofins Scientific SE is a global leader in the provision of analytical testing and scientific services. The company has a market capitalization of 13.54 billion as of 2022 and a return on equity of 12.32%. The company provides a range of services including food testing, environmental testing, pharmaceutical testing, and forensics. Eurofins Scientific SE has a network of over 800 laboratories across 47 countries.
Summary
Charles River Laboratories International, Inc. (CRL) is a leading provider of contract research services to the global life sciences industry. Recently, the company announced the acquisition of an 80% ownership stake in SAMDI Tech for $50M in cash. This strategic move is expected to further expand CRL’s capabilities in drug discovery and development, and could potentially provide additional revenue growth in the future.
It is also likely to strengthen CRL’s presence in the life sciences industry, as well as boost its competitive advantage in the market. Investors should monitor CRL’s progress in integrating the acquired company and assessing the impact of this acquisition on its financial performance.
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
